Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

PD-L1 Positive

The First Hospital of Jilin UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the PD-L1 Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Gilead Sciences
Phase 3B
Pembrolizumab
Gilead Sciences
Phase 3B
Epirubicin
Gilead Sciences
Phase 3B
Carboplatin
Gilead Sciences
Phase 3B
Toripalimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC

View all 12 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →